Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 10;9(1):25532.
doi: 10.52965/001c.25532. eCollection 2021.

Milnacipran for the Treatment of Fibromyalgia

Harshit Gupta  1 , Brook Girma  2 , Jack S Jenkins  2 , Sarah E Kaufman  2 , Christopher A Lee  3 , Alan D Kaye  2
Affiliations
Review

Milnacipran for the Treatment of Fibromyalgia

Harshit Gupta et al. Health Psychol Res. .

Abstract

Purpose of review: This is a comprehensive review of the literature regarding the use of milnacipran in treating fibromyalgia. A chronic pain disorder with other system disturbances, fibromyalgia is often resistant to many therapeutic approaches. This review presents the background, evidence, and indications for using milnacipran as a treatment option for this condition.

Recent findings: The definition of fibromyalgia has evolved over many years as it is a relatively tricky syndrome to measure objectively. Today, it is characterized by chronic, widespread pain accompanied by alterations in sleep, mood, and other behavioral aspects. A variety of therapeutic regimens currently used to treat the syndrome as a singular approach are rarely effective.Milnacipran is one of three drugs currently approved by the FDA for the treatment of fibromyalgia. It acts as a serotonin and norepinephrine reuptake inhibitor, which results in decreased pain transmission. Milnacipran remains an effective treatment option for fibromyalgia in adults and needs to be further evaluated with existing therapeutic approaches.

Summary: Fibromyalgia is a broad-spectrum disorder primarily characterized by chronic pain coupled with disturbances in cognitive functioning and sleep. The progression of this syndrome is often debilitating and significantly affects the quality of life. Milnacipran is one of three FDA-approved drugs used to alleviate the symptom burden and is comparatively more therapeutic in specific domains of fibromyalgia. A more holistic approach is needed to treat fibromyalgia effectively and further research, including direct comparison studies, should be conducted to fully evaluate the usefulness of this drug.

Keywords: fibromyalgia; milnacipran; savella; ssri/snri.

PubMed Disclaimer

References

    1. 1. Perrot S. Fibromyalgia: A misconnection in a multiconnected world? Eur J Pain. 2019;23(5):866-873. doi:10.1002/ejp.1367 - DOI - PubMed
    1. 2. Arnold LM, Bennett RM, Crofford LJ, et al. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019;20(6):611-628. doi:10.1016/j.jpain.2018.10.008 - DOI - PubMed
    1. 3. Galvez-Sánchez CM, Duschek S, Del Paso GAR. Psychological impact of fibromyalgia: Current perspectives. Psychol Res Behav Manag. 2019;12:117-127. doi:10.2147/PRBM.S178240 - DOI - PMC - PubMed
    1. 4. Borchers AT, Gershwin ME. Fibromyalgia: A Critical and Comprehensive Review. Clin Rev Allergy Immunol. 2015;49(2):100-151. doi:10.1007/s12016-015-8509-4 - DOI - PubMed
    1. 5. Uçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008;59(9):1279-1298. doi:10.1002/art.24000 - DOI - PubMed